Mannosamine-Modified Poly(lactic-co-glycolic acid)-Polyethylene Glycol Nanoparticles for the Targeted Delivery of Rifapentine and Isoniazid in Tuberculosis Therapy
Authors:
Open Access
- 22 April 2025
- journal article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (5) , 1021-1033
Abstract
Tuberculosis, caused by Mycobacterium tuberculosis, is the leading cause of mortality attributed to a single infectious agent. Following macrophage invasion, M. tuberculosis uses various mechanisms to evade immune responses and to resist antituberculosis drugs. This study aimed to develop a targeted drug delivery system utilizing mannosamine (MAN)-modified nanoparticles (NPs) composed of poly(lactic-co-glycolic acid)-polyethylene glycol (PLGA-PEG), loaded with rifapentine and isoniazid, to enhance macrophage-directed therapy and enhance bacterial elimination. PLGA-PEG copolymer was modified with mannosamine through an amidation reaction. Rifapentine- and isoniazid-loaded PLGA-PEG-MAN NPs were synthesized by using the double emulsion solvent evaporation technique. The NPs exhibited an average particle size of 117.67 nm and displayed favorable physicochemical properties without evidence of cellular or hemolytic toxicity. The drug loading rates were 11.73% for rifapentine and 5.85% for isoniazid. Sustained drug release was achieved over a period exceeding 72 h, with antibacterial activity remaining intact during encapsulation. Synergistic bactericidal effects were noted. Additionally, mannosamine-modified NPs enhanced the phagocytic activity of macrophages via mannose receptor-mediated endocytosis, thereby improving drug delivery efficiency and significantly boosting the antibacterial efficacy of the NPs within macrophages. Pathological staining and biochemical analysis of rat organs following intravenous injection indicated that the NPs did not cause any significant toxic side effects in vivo. The findings of this study indicate that mannosamine-modified PLGA-PEG NPs loaded with rifapentine and isoniazid represent a promising drug delivery system for targeting macrophages to enhance the efficacy of antitubercular therapy.Keywords
Funding Information
- National Natural Science Foundation of China (82172454)
This publication has 55 references indexed in Scilit:
- NIR‐II AIE Luminogen‐Based Erythrocyte‐Like Nanoparticles with Granuloma‐Targeting and Self‐Oxygenation Characteristics for Combined Phototherapy of TuberculosisAdvanced Materials, 2024
- Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting MacrophagesAdvanced Therapeutics, 2022
- Mannose-conjugated chitosan nanoparticles for delivery of Rifampicin to Osteoarticular tuberculosisDrug Delivery and Translational Research, 2021
- Inhalable solid lipid nanoparticles for intracellular tuberculosis infection therapy: macrophage-targeting and pH-sensitive propertiesDrug Delivery and Translational Research, 2020
- Dual delivery of tuberculosis drugs via cyclodextrin conjugated curdlan nanoparticles to infected macrophagesCarbohydrate Polymers, 2019
- Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapyDrug Delivery and Translational Research, 2018
- Effects of Particle Size and Surface Modification on Cellular Uptake and Biodistribution of Polymeric Nanoparticles for Drug DeliveryPharmaceutical Research, 2013
- Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potentialBiomaterials, 2007
- M. tuberculosis and M. leprae Translocate from the Phagolysosome to the Cytosol in Myeloid CellsCell, 2007
- Mode of action of antituberculous drugs and mechanisms of drug resistance in Mycobacterium tuberculosisResearch in Microbiology, 1993